摘要
目的探讨双歧杆菌三联活菌胶囊联合曲美布汀对肠易激综合征(IBS)患者血清炎症因子水平的影响及疗效观察。方法选取内科门诊就诊的IBS患者72例,随机分为联合组36例和对照组36例。两组患者均予以饮食调整、胃肠解痉药、止泻药和维持水电解质酸碱平衡等等基础治疗。联合组患者予以双歧杆菌三联活菌胶囊(0.42 g,3次/d,温开水溶解后口服)联合曲美布汀(曲美布汀片0.20 g,3次/d,口服)治疗,对照组患者予以单纯的曲美布汀治疗,剂量与方法同联合组,两组疗程均为6周。观察两组患者治疗前后血清白介素-6(IL-6)、IL-8和IL-10水平变化,并比较其临床疗效和不良反应。结果治疗6周后,两组患者血清IL-6和IL-8水平较前明显下降,IL-10水平较前明显上升(P<0.05或P<0.01),且联合组下降或上升幅度明显大于对照组(P<0.05);联合组患者临床总有效率明显高于对照组(χ2=4.18,P<0.05),两组治疗中共发生不良反应6例,其中对照组2例,联合组4例,症状均较轻微,两组不良反应发生率比较差异无统计学意义(χ2=0.18,P>0.05)。结论双歧杆菌三联活菌胶囊联合曲美布汀治疗IBS的疗效明显优于单纯的曲美布汀治疗,安全性较好,作用可能与其能降低血清IL-6和IL-8水平,升高血清IL-10水平,纠正促炎症因子与抗炎症因子比例失调,减轻炎症反应级联效应密切相关。
Objective To discuss the influence and efficacy of Bifid Triple Viable Capsules combined with Trimebutine on serum inflammatory factor levels of patients with irritable bowel syndrome （IBS）. Methods 72 outpatients with IBS, who were given medical treatment in our Department of Gastroenterology, were selected and divided into combination group and control group at random, with 36 cases in either group. Both groups were given basic treatments ubckydubg diet adjustment, gastrointestinal antispasmodic drug, antidiarrheal agent and maintenance of water, electrolyte and acid-base balance etc. The combination group were additionally given 0. 42 g of Bifid Triple Viable Capsules and 0. 20 g of Trimebutine tablet orally t. i. d. , while the control group were only given TrimebutiMe tablet with the same dose and method. The courses of treatment were 6 weeks. The changes of serum IL-6, -8 and -10 levels in both groups before and after treatment were observed, and the clinical efficacy and untoward effect were compared as well. Results After 6 weeks＇ treatment, the serum IL-6 and -8 levels of patients in both groups obviously declined, while the IL-10 level obviously rose than before （ P 〈 0.05 or P 〈 0. 01 ）, and the declining or rising rate in combination group were much higher than that in control group （ P 〈 0.05 ）. The total clinical efficiency in combination group was much higher than that in control group （x^2 = 4. 18, P 〈 0. 05 ）. 6 cases of untoward effect appeared during the treatment, 2 cases in control group and 4 cases in combination group, with mild symptoms ; The difference was not statistically obvious （x^2 = 0. 18, P 〉 0. 05 ）. Conclusion Compared with Trimebutine alone, Bifid Triple Viable Capsules combined with Trimebutine has better curative effect on IBS with high safety, the mechanism of action of which may be closely associated with the reduction of IL-6 and -8 levels, rise of serum IL-10 level, adjustment of the imbalance of proinflammatory/anti-inflammatory factor levels, and alleviation of inflammatory response cascade effect.
出处
《中国微生态学杂志》
CAS
CSCD
2014年第12期1414-1417,共4页
Chinese Journal of Microecology
